PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Premera Blue CrossCommercial · Prior Auth · Medical Policy · WA, AK · Allergy & Immunology, Oncology, Rheumatology +14 moreHigh impact

Medical Policy and Coding Updates - February 2025

Effective date
Not stated in the notice
Identified
Jun 16, 2026

Summary

Premera's February 2025 update adds carpal tunnel release as a new surgical policy effective May 6, 2025, and changes IL-5 inhibitor and Dupixent asthma criteria, including the blood eosinophil count, which was lowered from 300 to 150 cells/mcL. It also moves Briumvi, Lemtrada, Ocrevus, Ocrevus Zunovo, Tyruko and Tysabri from the multiple sclerosis policy into a new Gene Therapies for Rare Diseases policy effective February 1, 2025, and removes site-of-service review from many infusion and biologic codes while keeping medical necessity and prior authorization review.

Get alerts when payers change rules like this one

We check Premera Blue Cross and other payers every day and email you when a change matches your specialty and state.

Get Premera Blue Cross alertsPolicy Monitoring is free. No card required.

What to do

Action · 6 steps
01Already effective February 1, 2025, February 7, 2025, March 5, 2025, April 6, 2025 and May 6, 2025, so check current applicability before acting on these past dates.
02Billing team: for Premera HMO members, J0850, J7351 and 90291 (Medical Necessity Criteria for Pharmacy Edits) and J9034, J9036, J9056, J9153, J9266 and J9268 (Miscellaneous Oncology Drugs) now require review for medical necessity and prior authorization, effective February 7, 2025.
03Billing team: for the codes listed under the February 1, 2025 revisions, including J0256, J0598, J2786, J9271 and J9299, site-of-service review no longer applies, but review for medical necessity and prior authorization is still required.
04Billing team: CAR-T codes 38225, 38226 and 38227 no longer require review, effective February 1, 2025.
05Billing team: under Gene Therapies for Rare Diseases (policy 5.01.644), effective February 1, 2025, in accordance with Alaska law (HB 226) site of service is not applicable to fully-insured members in Alaska, so refer to the infusion drug medical necessity criteria only.
06Billing team: carpal tunnel release is considered medically necessary for individuals with carpal tunnel syndrome who have failed conservative therapy when criteria are met, effective May 6, 2025.

Codes mentioned

J0850J735190291J9034J9036J9056J9153J9266J9268J0256J1300J1303J0180J0221J0584J1322J1458J1743J1786J1931J2840J3060J3385J3397J0598J2786J9271J9299J1459J1551J1552J1554J1555J1556J1557J1558J1559J1561J1566J1568J1569J1572J1575J1576J159990283J2323J2329J2350Q5134J0485J1426J1428J1429J1745J1747Q5103Q5104Q5121J0791J0129J1602J3247J3262Q5133J3380Q5115Q5119Q5123J2327J3358J0490J1823J931238225382263822792972

Original notice

Medical Policy and Coding Updates - February 2025
premera.com · Always check the source before changing claims.
View original ↗

Related policy hubs

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account